677 related articles for article (PubMed ID: 20424012)
1. Isolation and characterization of circulating tumor cells from patients with localized and metastatic prostate cancer.
Stott SL; Lee RJ; Nagrath S; Yu M; Miyamoto DT; Ulkus L; Inserra EJ; Ulman M; Springer S; Nakamura Z; Moore AL; Tsukrov DI; Kempner ME; Dahl DM; Wu CL; Iafrate AJ; Smith MR; Tompkins RG; Sequist LV; Toner M; Haber DA; Maheswaran S
Sci Transl Med; 2010 Mar; 2(25):25ra23. PubMed ID: 20424012
[TBL] [Abstract][Full Text] [Related]
2. The Use of a New CellCollector to Isolate Circulating Tumor Cells from the Blood of Patients with Different Stages of Prostate Cancer and Clinical Outcomes - A Proof-of-Concept Study.
Theil G; Fischer K; Weber E; Medek R; Hoda R; Lücke K; Fornara P
PLoS One; 2016; 11(8):e0158354. PubMed ID: 27479125
[TBL] [Abstract][Full Text] [Related]
3. Functional characterization of circulating tumor cells with a prostate-cancer-specific microfluidic device.
Kirby BJ; Jodari M; Loftus MS; Gakhar G; Pratt ED; Chanel-Vos C; Gleghorn JP; Santana SM; Liu H; Smith JP; Navarro VN; Tagawa ST; Bander NH; Nanus DM; Giannakakou P
PLoS One; 2012; 7(4):e35976. PubMed ID: 22558290
[TBL] [Abstract][Full Text] [Related]
4. Limited prognostic value of preoperative circulating tumor cells for early biochemical recurrence in patients with localized prostate cancer.
Meyer CP; Pantel K; Tennstedt P; Stroelin P; Schlomm T; Heinzer H; Riethdorf S; Steuber T
Urol Oncol; 2016 May; 34(5):235.e11-6. PubMed ID: 26795608
[TBL] [Abstract][Full Text] [Related]
5. High detection rate of circulating tumor cells in blood of patients with prostate cancer using telomerase activity.
Fizazi K; Morat L; Chauveinc L; Prapotnich D; De Crevoisier R; Escudier B; Cathelineau X; Rozet F; Vallancien G; Sabatier L; Soria JC
Ann Oncol; 2007 Mar; 18(3):518-21. PubMed ID: 17322541
[TBL] [Abstract][Full Text] [Related]
6. Tumorigenic potential of circulating prostate tumor cells.
Carvalho FL; Simons BW; Antonarakis ES; Rasheed Z; Douglas N; Villegas D; Matsui W; Berman DM
Oncotarget; 2013 Mar; 4(3):413-21. PubMed ID: 23530114
[TBL] [Abstract][Full Text] [Related]
7. Metabolic reprogramming-based characterization of circulating tumor cells in prostate cancer.
Chen J; Cao S; Situ B; Zhong J; Hu Y; Li S; Huang J; Xu J; Wu S; Lin J; Zhao Q; Cai Z; Zheng L; Wang Q
J Exp Clin Cancer Res; 2018 Jun; 37(1):127. PubMed ID: 29954422
[TBL] [Abstract][Full Text] [Related]
8. Single-cell analysis of circulating tumor cells identifies cumulative expression patterns of EMT-related genes in metastatic prostate cancer.
Chen CL; Mahalingam D; Osmulski P; Jadhav RR; Wang CM; Leach RJ; Chang TC; Weitman SD; Kumar AP; Sun L; Gaczynska ME; Thompson IM; Huang TH
Prostate; 2013 Jun; 73(8):813-26. PubMed ID: 23280481
[TBL] [Abstract][Full Text] [Related]
9. Circulating tumor cells in localized prostate cancer: isolation, cultivation in vitro and relationship to T-stage and Gleason score.
Kolostova K; Broul M; Schraml J; Cegan M; Matkowski R; Fiutowski M; Bobek V
Anticancer Res; 2014 Jul; 34(7):3641-6. PubMed ID: 24982381
[TBL] [Abstract][Full Text] [Related]
10. Phenotypic Profiling of Circulating Tumor Cells in Metastatic Prostate Cancer Patients Using Nanoparticle-Mediated Ranking.
Green BJ; Nguyen V; Atenafu E; Weeber P; Duong BTV; Thiagalingam P; Labib M; Mohamadi RM; Hansen AR; Joshua AM; Kelley SO
Anal Chem; 2019 Aug; 91(15):9348-9355. PubMed ID: 31264404
[TBL] [Abstract][Full Text] [Related]
11. Circulating prostate tumor cells detected by reverse transcription-PCR in men with localized or castration-refractory prostate cancer: concordance with CellSearch assay and association with bone metastases and with survival.
Helo P; Cronin AM; Danila DC; Wenske S; Gonzalez-Espinoza R; Anand A; Koscuiszka M; Väänänen RM; Pettersson K; Chun FK; Steuber T; Huland H; Guillonneau BD; Eastham JA; Scardino PT; Fleisher M; Scher HI; Lilja H
Clin Chem; 2009 Apr; 55(4):765-73. PubMed ID: 19233911
[TBL] [Abstract][Full Text] [Related]
12. Multigene model for predicting metastatic prostate cancer using circulating tumor cells by microfluidic magnetophoresis.
Cho H; Chung JI; Kim J; Seo WI; Lee CH; Morgan TM; Byun SS; Chung JS; Han KH
Cancer Sci; 2021 Feb; 112(2):859-870. PubMed ID: 33232539
[TBL] [Abstract][Full Text] [Related]
13. Multigene reverse transcription-PCR profiling of circulating tumor cells in hormone-refractory prostate cancer.
O'Hara SM; Moreno JG; Zweitzig DR; Gross S; Gomella LG; Terstappen LW
Clin Chem; 2004 May; 50(5):826-35. PubMed ID: 14988224
[TBL] [Abstract][Full Text] [Related]
14. Detection of live circulating tumor cells by a class of near-infrared heptamethine carbocyanine dyes in patients with localized and metastatic prostate cancer.
Shao C; Liao CP; Hu P; Chu CY; Zhang L; Bui MH; Ng CS; Josephson DY; Knudsen B; Tighiouart M; Kim HL; Zhau HE; Chung LW; Wang R; Posadas EM
PLoS One; 2014; 9(2):e88967. PubMed ID: 24551200
[TBL] [Abstract][Full Text] [Related]
15. The Novel Association of Circulating Tumor Cells and Circulating Megakaryocytes with Prostate Cancer Prognosis.
Xu L; Mao X; Guo T; Chan PY; Shaw G; Hines J; Stankiewicz E; Wang Y; Oliver RTD; Ahmad AS; Berney D; Shamash J; Lu YJ
Clin Cancer Res; 2017 Sep; 23(17):5112-5122. PubMed ID: 28615267
[No Abstract] [Full Text] [Related]
16. Sample-to-Answer Isolation and mRNA Profiling of Circulating Tumor Cells.
Mohamadi RM; Ivanov I; Stojcic J; Nam RK; Sargent EH; Kelley SO
Anal Chem; 2015 Jun; 87(12):6258-64. PubMed ID: 26009151
[TBL] [Abstract][Full Text] [Related]
17. Circulating Tumor Cells in Biochemical Recurrence of Prostate Cancer.
Aragon-Ching JB; Siegel RS; Frazier H; Andrawis R; Hendricks F; Phillips M; Jarrett T; Guebre-Xabiher H; Patierno S; Simmens SJ
Clin Genitourin Cancer; 2015 Oct; 13(5):e341-5. PubMed ID: 25956468
[TBL] [Abstract][Full Text] [Related]
18. Molecular Profiling of Pooled Circulating Tumor Cells from Prostate Cancer Patients Using a Dual-Antibody-Functionalized Microfluidic Device.
Yin C; Wang Y; Ji J; Cai B; Chen H; Yang Z; Wang K; Luo C; Zhang W; Yuan C; Wang F
Anal Chem; 2018 Mar; 90(6):3744-3751. PubMed ID: 29464943
[TBL] [Abstract][Full Text] [Related]
19. Isolation and genomic analysis of circulating tumor cells from castration resistant metastatic prostate cancer.
Magbanua MJ; Sosa EV; Scott JH; Simko J; Collins C; Pinkel D; Ryan CJ; Park JW
BMC Cancer; 2012 Feb; 12():78. PubMed ID: 22373240
[TBL] [Abstract][Full Text] [Related]
20. Assessment of circulating tumor cells (CTCs) in prostate cancer patients with low-volume tumors.
Ali A; Furusato B; Ts'o PO; Lum ZP; Elsamanoudi S; Mohamed A; Srivastava S; Moul JW; Brassell SA; Sesterhenn IA; McLeod DG
Pathol Int; 2010 Oct; 60(10):667-72. PubMed ID: 20846264
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
